Segment & Geographic Data
Quant-Grade Normalized Data
API & CSV Delivery
Chembio Diagnostics Inc's Business Segments
Chembio Diagnostics Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Reportable Segments
-
Largest Segment
-
Total Revenue
-
Regions Reported
4
Annual Results
Revenue Share by Region -
- Latin America38.9%
- Africa14.1%
- Europe Middle East9.1%
- Asia1.3%
Revenue by Geographic Region -
| Region | Revenue (Millions) | % of Total |
|---|---|---|
| Latin America | $ 19 | 38.9% |
| Africa | $ 7 | 14.1% |
| Europe Middle East | $ 5 | 9.1% |
1 more regions available
Sign in to unlock the full Chembio Diagnostics Inc dataset.
Revenue by Product & Service Category -
- Product95.1%
- Grant2.4%
- License2.3%
- Research and Development Revenue0.2%
Revenue by Product & Service Category -
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Product | $ 47 | 95.1% |
| Grant | $ 1 | 2.4% |
| License | $ 1 | 2.3% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
1 more categories available
Sign in to unlock the full Chembio Diagnostics Inc dataset.
Description of Chembio Diagnostics Inc
Chembio Diagnostics Inc. is a leading global diagnostics company specializing in creating effective and innovative diagnostic tests for a variety of diseases and conditions. With over three decades of experience, the company has become a trusted name in the industry, known for its commitment to improving global health outcomes.
Chembio Diagnostics focuses on developing rapid point-of-care (POC) diagnostic tests that are easy to use, accurate, and cost-effective. Their tests are designed to provide rapid, reliable results within minutes, enabling healthcare professionals to make quick and informed decisions for patient care.
The company's product portfolio covers a diverse range of infectious diseases, including HIV, Zika virus, Ebola, COVID-19, and hepatitis. Chembio Diagnostics has developed multiple innovative technologies to detect and monitor these diseases, including lateral flow immunoassay (LFI), Dual Path Platform (DPP®), and SURE CHECK® rapid HIV tests.
One of the standout products from Chembio Diagnostics is its DPP® technology, which offers superior sensitivity, specificity, and ease of use compared to traditional testing methods. This technology allows for simultaneous detection of multiple disease markers, providing a comprehensive diagnostic solution for healthcare providers.
Chembio Diagnostics collaborates with various partners, including governmental organizations, non-profit entities, and commercial entities, to develop and distribute its diagnostic tests globally. The company operates in both the developed and developing world, aiming to make a positive impact on public health across all regions.
In addition to its focus on infectious disease diagnostics, Chembio Diagnostics also provides contract development and manufacturing services to other diagnostic companies, leveraging its expertise in rapid test development and manufacturing.
The company is committed to meeting regulatory standards and has obtained several certifications and approvals, including the U.S. Food and Drug Administration (FDA) approval for numerous products. Chembio Diagnostics also maintains high-quality standards by operating under the guidelines of ISO 13485, an international standard for medical device quality management systems.
Chembio Diagnostics places a strong emphasis on research and development, investing significant resources to stay at the forefront of diagnostic technology. The company's highly skilled team of scientists and engineers continuously strives to develop innovative solutions to address new and emerging healthcare challenges.
Overall, Chembio Diagnostics Inc. is a highly respected diagnostics company that plays a crucial role in global healthcare by providing rapid, accurate, and user-friendly diagnostic tests. Through its commitment to innovation and collaboration, the company continues to make significant contributions in the fight against infectious diseases worldwide.
Chembio Diagnostics focuses on developing rapid point-of-care (POC) diagnostic tests that are easy to use, accurate, and cost-effective. Their tests are designed to provide rapid, reliable results within minutes, enabling healthcare professionals to make quick and informed decisions for patient care.
The company's product portfolio covers a diverse range of infectious diseases, including HIV, Zika virus, Ebola, COVID-19, and hepatitis. Chembio Diagnostics has developed multiple innovative technologies to detect and monitor these diseases, including lateral flow immunoassay (LFI), Dual Path Platform (DPP®), and SURE CHECK® rapid HIV tests.
One of the standout products from Chembio Diagnostics is its DPP® technology, which offers superior sensitivity, specificity, and ease of use compared to traditional testing methods. This technology allows for simultaneous detection of multiple disease markers, providing a comprehensive diagnostic solution for healthcare providers.
Chembio Diagnostics collaborates with various partners, including governmental organizations, non-profit entities, and commercial entities, to develop and distribute its diagnostic tests globally. The company operates in both the developed and developing world, aiming to make a positive impact on public health across all regions.
In addition to its focus on infectious disease diagnostics, Chembio Diagnostics also provides contract development and manufacturing services to other diagnostic companies, leveraging its expertise in rapid test development and manufacturing.
The company is committed to meeting regulatory standards and has obtained several certifications and approvals, including the U.S. Food and Drug Administration (FDA) approval for numerous products. Chembio Diagnostics also maintains high-quality standards by operating under the guidelines of ISO 13485, an international standard for medical device quality management systems.
Chembio Diagnostics places a strong emphasis on research and development, investing significant resources to stay at the forefront of diagnostic technology. The company's highly skilled team of scientists and engineers continuously strives to develop innovative solutions to address new and emerging healthcare challenges.
Overall, Chembio Diagnostics Inc. is a highly respected diagnostics company that plays a crucial role in global healthcare by providing rapid, accurate, and user-friendly diagnostic tests. Through its commitment to innovation and collaboration, the company continues to make significant contributions in the fight against infectious diseases worldwide.
Chembio Diagnostics Inc. is a biomedical company that focuses on the development and commercialization of diagnostic tests and products. The company specializes primarily in point-of-care (POC) testing, which is designed to provide rapid and accurate diagnostic results at the time and place of patient care. This type of testing is crucial in various healthcare settings, facilitating immediate decision-making and treatment.
Segments
Chembio operates in several key segments, including:
1. Infectious Disease Diagnostics: This is one of Chembios core areas, concentrating on the development of tests for various infectious diseases. The focus here is typically on diseases that require quick diagnosis to initiate timely treatment.
2. Women’s Health: This segment involves developing diagnostic tests targeted specifically at womens health issues, such as reproductive health diseases, pregnancy testing, and sexually transmitted infections.
3. Multi-Analyte Testing: Chembio is also involved in creating tests that can simultaneously detect multiple analytes. This capability enhances the efficiency of the diagnostic process and improves patient care by allowing for more comprehensive evaluations with fewer tests.
Products
Chembio offers a range of products across its segments, primarily associated with rapid testing technologies. Some of the notable products include:
1. DPP® (Dual Path Platform): This proprietary platform is foundational to Chembios diagnostic offerings. It is designed for serological testing, providing quick results for various infectious diseases. The technology can be utilized to detect antibodies or antigens in a patient’s sample, enabling the diagnosis of conditions such as HIV and viral hepatitis.
2. HIV Testing: Chembio has developed several products for the rapid testing of HIV, including tests that can deliver results in as little as 20 minutes. These products are crucial for healthcare providers, especially in areas with limited access to laboratory facilities.
3. Malaria Rapid Tests: The company also has a focus on malaria diagnostics, providing rapid tests that detect the presence of malaria parasites in blood samples. Given the global burden of malaria, these tests are vital for timely diagnosis and treatment.
4. Syphilis Testing: Chembio offers products that allow for the rapid detection of syphilis, another important sexually transmitted infection. The availability of rapid testing can greatly improve early identification and treatment, thus reducing the risk of transmission.
5. COVID-19 Testing: In response to the global pandemic, Chembio developed solutions to facilitate rapid testing for COVID-19. Their tests aim to provide timely and accurate results to help manage the outbreak effectively.
Services
In addition to products, Chembio Diagnostics Inc. offers several services that complement its core offerings:
1. Technical Support and Training: Chembio provides training and technical assistance for healthcare personnel to ensure the effective use of their diagnostic tests. This includes guidance on sample collection, test administration, and result interpretation, enabling healthcare providers to maximize the utility of Chembio’s products.
2. Partnerships and Collaborations: Chembio often collaborates with other companies, research institutions, and health organizations to enhance its testing capabilities and expand its product offerings. These partnerships help to integrate new technologies and expand market reach.
3. Regulatory Support: The company is actively involved in navigating the complex regulatory landscape for diagnostic products. This includes obtaining the necessary approvals from health authorities to ensure their products meet safety and efficacy standards.
4. Custom Testing Solutions: Chembio may offer customized solutions for testing needs based on specific client or market requirements, leveraging their technology to create tailored diagnostic tests.
Overall, Chembio Diagnostics Inc. is committed to improving global health outcomes through innovative diagnostic solutions, with a strong emphasis on rapid testing technologies that cater to infectious diseases and womens health. Their extensive product portfolio and supportive services are designed to enable healthcare providers to deliver effective care in diverse settings.
Segments
Chembio operates in several key segments, including:
1. Infectious Disease Diagnostics: This is one of Chembios core areas, concentrating on the development of tests for various infectious diseases. The focus here is typically on diseases that require quick diagnosis to initiate timely treatment.
2. Women’s Health: This segment involves developing diagnostic tests targeted specifically at womens health issues, such as reproductive health diseases, pregnancy testing, and sexually transmitted infections.
3. Multi-Analyte Testing: Chembio is also involved in creating tests that can simultaneously detect multiple analytes. This capability enhances the efficiency of the diagnostic process and improves patient care by allowing for more comprehensive evaluations with fewer tests.
Products
Chembio offers a range of products across its segments, primarily associated with rapid testing technologies. Some of the notable products include:
1. DPP® (Dual Path Platform): This proprietary platform is foundational to Chembios diagnostic offerings. It is designed for serological testing, providing quick results for various infectious diseases. The technology can be utilized to detect antibodies or antigens in a patient’s sample, enabling the diagnosis of conditions such as HIV and viral hepatitis.
2. HIV Testing: Chembio has developed several products for the rapid testing of HIV, including tests that can deliver results in as little as 20 minutes. These products are crucial for healthcare providers, especially in areas with limited access to laboratory facilities.
3. Malaria Rapid Tests: The company also has a focus on malaria diagnostics, providing rapid tests that detect the presence of malaria parasites in blood samples. Given the global burden of malaria, these tests are vital for timely diagnosis and treatment.
4. Syphilis Testing: Chembio offers products that allow for the rapid detection of syphilis, another important sexually transmitted infection. The availability of rapid testing can greatly improve early identification and treatment, thus reducing the risk of transmission.
5. COVID-19 Testing: In response to the global pandemic, Chembio developed solutions to facilitate rapid testing for COVID-19. Their tests aim to provide timely and accurate results to help manage the outbreak effectively.
Services
In addition to products, Chembio Diagnostics Inc. offers several services that complement its core offerings:
1. Technical Support and Training: Chembio provides training and technical assistance for healthcare personnel to ensure the effective use of their diagnostic tests. This includes guidance on sample collection, test administration, and result interpretation, enabling healthcare providers to maximize the utility of Chembio’s products.
2. Partnerships and Collaborations: Chembio often collaborates with other companies, research institutions, and health organizations to enhance its testing capabilities and expand its product offerings. These partnerships help to integrate new technologies and expand market reach.
3. Regulatory Support: The company is actively involved in navigating the complex regulatory landscape for diagnostic products. This includes obtaining the necessary approvals from health authorities to ensure their products meet safety and efficacy standards.
4. Custom Testing Solutions: Chembio may offer customized solutions for testing needs based on specific client or market requirements, leveraging their technology to create tailored diagnostic tests.
Overall, Chembio Diagnostics Inc. is committed to improving global health outcomes through innovative diagnostic solutions, with a strong emphasis on rapid testing technologies that cater to infectious diseases and womens health. Their extensive product portfolio and supportive services are designed to enable healthcare providers to deliver effective care in diverse settings.